Scarica l'app Stockscreener
21.45
0.14%
0.03
Dopo l'orario di chiusura:
21.40
-0.05
-0.23%
Precedente Chiudi:
$21.42
Aprire:
$21.43
Volume 24 ore:
1.40M
Relative Volume:
0.34
Capitalizzazione di mercato:
$2.22B
Reddito:
$158.18M
Utile/perdita netta:
$-107.32M
Rapporto P/E:
-20.58
EPS:
-1.0421
Flusso di cassa netto:
$-107.58M
1 W Prestazione:
+0.23%
1M Prestazione:
+106.85%
6M Prestazione:
+188.69%
1 anno Prestazione:
+169.13%
Intervallo 1D:
$21.42
$21.47
Intervallo di 1 settimana:
$21.39
$21.47
Portata 52W:
$5.635
$21.47
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Nome
Day One Biopharmaceuticals Inc
Settore
Industria
Telefono
650 484-0899
Indirizzo
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
21.45 | 2.22B | 158.18M | -107.32M | -107.58M | -1.0421 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2026-01-13 | Ripresa | TD Cowen | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-10-09 | Reiterato | Needham | Buy |
| 2024-08-01 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2024-04-24 | Reiterato | Needham | Buy |
| 2023-04-25 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-08 | Iniziato | CapitalOne | Overweight |
| 2023-02-03 | Iniziato | Oppenheimer | Perform |
| 2022-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-12-05 | Iniziato | Goldman | Buy |
| 2022-12-01 | Iniziato | BofA Securities | Buy |
Mostra tutto
Day One Biopharmaceuticals Inc Borsa (DAWN) Ultime notizie
Day One Biopharmaceuticals price target raised to $36 from $32 at JPMorgan - tipranks.com
SG Americas Securities LLC Buys 323,747 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
DAWN Stock Price, Quote & Chart | DAY ONE BIOPHARMACEUTICALS I (NASDAQ:DAWN) - ChartMill
Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 12-Month HighShould You Buy? - MarketBeat
Baker McKenzie Advises Servier on the Acquisition of Day One Biopharmaceuticals for Approximately USD 2.5 Billion - Legal Desire Media and Insights
DAWN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hennion & Walsh Asset Management Inc. Buys 218,383 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Breakout Move: Is Day One Biopharmaceuticals Inc a turnaround storyWeekly Stock Summary & Community Verified Trade Signals - baoquankhu1.vn
Earnings Miss: Is Day One Biopharmaceuticals Inc a top pick in the sectorTake Profit & Safe Capital Growth Stock Tips - baoquankhu1.vn
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Down 20.3% in March - marketbeat.com
Day One Biopharmaceuticals (DAWN) price target decreased by 10.27% to 21.16 - MSN
(DAWN) Risk Channels and Responsive Allocation - Stock Traders Daily
Are SEM, DAWN, VRE Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Day One Biopharmaceuticals Executives Sell Shares Amid Legal Firm's Scrutiny of $21.50 Offer - Bitget
Vanguard amends holdings for Day One Biopharmaceuticals (NASDAQ: DAWN), reports 0 shares - Stock Titan
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc.DAWN - The AI Journal
Servier adds exhibit to Day One Biopharma tender offer (DAWN) - Stock Titan
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year HighHere's What Happened - marketbeat.com
Servier offers $21.50 per share for Day One (NASDAQ: DAWN) in agreed deal - Stock Titan
Servier (DAWN) offers $21.50 in cash to buy Day One Biopharma shares - Stock Titan
GLAZER CAPITAL, LLC Acquires Significant Stake in Day One Biopha - GuruFocus
GLAZER CAPITAL, LLC Acquires Significant Stake in Day One Biopharmaceuticals Inc - gurufocus.com
Biggest stock movers Friday: MRVL, GAP, DAWN, GPRO, and more - MSN
SunOpta Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SunOpta Inc.STKL - Business Wire
Servier (DAWN) plans tender offer under March 6, 2026 merger agreement - Stock Titan
Aug Breakouts: Will Day One Biopharmaceuticals Inc stock go up in YEAR2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Day One Biopharmaceuticals stock hits 52-week high at $21.44 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Day One Biopharmaceuticals stock hits 52-week high at $21.44 - Investing.com
Glazer Capital (NASDAQ: DAWN) reports 5.6M-share, 5.44% stake - Stock Titan
Take Profit: Is Day One Biopharmaceuticals Inc a strong growth stockStock Surge & AI Driven Stock Reports - baoquankhu1.vn
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration - MSN
Trading Action: What are the future prospects of Day One Biopharmaceuticals IncRisk Management & AI Forecasted Stock Moves - baoquankhu1.vn
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
(DAWN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Algert Global LLC Buys 411,000 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? - Sahm
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - Sahm
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
symbol__ Stock Quote Price and Forecast - CNN
HC Wainwright & Co. downgrades Day One Biopharmaceuticals (DAWN) - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
EDGAR Filing Documents for 0001193125-24-108544 - SEC.gov
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals Inc Azioni (DAWN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Day One Biopharmaceuticals Inc Azioni (DAWN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dubow Adam | Gen Counsel & Secretary |
Feb 17 '26 |
Sale |
11.60 |
6,395 |
74,188 |
72,694 |
| York Charles N II | COO and CFO |
Feb 17 '26 |
Sale |
11.60 |
6,065 |
70,359 |
312,025 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Feb 17 '26 |
Sale |
11.60 |
15,459 |
179,338 |
204,603 |
| VASCONCELLES MICHAEL | Head of Research and Dev. |
Feb 17 '26 |
Sale |
11.60 |
2,728 |
31,647 |
4,397 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):